ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Up 11.8% in January

ADMA Biologics, Inc. (NASDAQ:ADMA) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 13,620,000 shares, an increase of 11.8% from the December 31st total of 12,180,000 shares. Based on an average daily volume of 3,500,000 shares, the short-interest ratio is currently 3.9 days.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Trading Up 0.3 %

Shares of NASDAQ:ADMA opened at $16.15 on Friday. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of 57.68 and a beta of 0.76. ADMA Biologics has a 1-year low of $5.02 and a 1-year high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a 50 day moving average price of $18.10 and a 200 day moving average price of $17.55.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the prior year, the firm earned $0.01 EPS. On average, research analysts anticipate that ADMA Biologics will post 0.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds have recently made changes to their positions in the company. USA Financial Formulas lifted its position in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 539 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 888 shares in the last quarter. GAMMA Investing LLC lifted its position in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares in the last quarter. State of Alaska Department of Revenue lifted its position in ADMA Biologics by 1.0% in the 4th quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company’s stock worth $2,304,000 after buying an additional 1,337 shares in the last quarter. Finally, Hollencrest Capital Management purchased a new stake in ADMA Biologics in the 3rd quarter worth approximately $30,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.